Co-Infection Dynamics of COVID-19 and Monkeypox: Implications for Disease Severity, Viral Transmission, and Vaccine Efficacy

Strategic Insights -

Research findings on the co-infection dynamics of COVID-19 and Monkeypox (Mpox) have been discussed in a new report by scientists at Georgia Southern University. The study highlights the importance of understanding the relationship between these two viral infections, which have similar modes of presentation, diagnosis, and treatment strategies. The research aims to determine the relationship between dynamicity and immune response interactions between Mpox and COVID-19, focusing on the implications for disease severity, viral transmission, and vaccine efficacy.

Key Takeaways:

  • Several co-infections between COVID-19 and Mpox have been reported, including a case in Florida, USA, and others in Barcelona, Spain, and Italy.
  • Both COVID-19 and Mpox have been shown to have some effects on the immunity of a person, especially the innate system, which can occasionally produce inadvertent effects.
  • A common factor that links the two diseases is the endoglycosidase named Heparanase (HPSE).
  • Both COVID-19 and Mpox clinical features have bizarre severity and complications.
  • The rising co-infection of COVID-19 and increased Mpox infection rate has led to the development of only approved vaccines JYNNEOS and COH04S1.
  • Global efforts such as awareness campaigns, research, and interprofessional measures among the concerned countries and policymakers are needed to give more insights into both diseases.
  • The study emphasizes the importance of interprofessional collaboration and coordination among countries and policymakers in addressing the co-infection dynamics of COVID-19 and Mpox.
  • The researchers suggest that experimental studies, cohort studies, case series, and other types of research should be conducted to gain a deeper understanding of the relationship between COVID-19 and Mpox.
  • The study also highlights the need for adequate political will, funding, and the establishment of research facilities to address the rising co-infection rates of COVID-19 and Mpox.

Statistics:

  • 22: The volume number of the Virology Journal where the study was published.
  • 1-10: The page numbers of the study.
  • 2014-2024: The decade during which the researchers conducted their literature review using PubMed, Google Scholar, and Web of Science.
  • 10.1186/s12985-025-02857-w: The digital object identifier of the study.
  • 56 years old: The age of the man in Barcelona, Spain, who suffered from both Mpox and COVID-19.
  • 36 years old: The age of the man in Italy who suffered from both Mpox and COVID-19.

Sources:

  • Virology Journal, 2025,22(1):1-10. (Virology Journal - http://virologyj.biomedcentral.com)
  • Exploring co-infection dynamics and immune response interactions between COVID-19 and Monkeypox: implications for disease severity, viral transmission, and vaccine efficacy. (Virology Journal)
  • Georgia Southern University
  • NewsRx LLC
  • Medical Letter on the CDC & FDA